January 01, 2018. doi:10.12123/npcd201801001
BIOWED January 01, 2018 To read the full article
Metrics: PDF views | HTML views
Dan Zhang, Jiaru Luo, Yunzhi Ling*
All authors are from Biowed (China) Co., Ltd.
Keywords: XRCC1; Polymorphisms; Glioma; Meta-analysis
Received: September 01,2017 Accept: November 01,2017 published:January 01,2018
Gliomas are one of the most common malignant tumors in the central nervous system. At present, many publications have assessed the association between the polymorphisms of XRCC1 and glioma susceptibility. However, the results remain inconclusive. In this study, we aimed to exhaustively assess the association between the polymorphisms of XRCC1 (including Arg194Trp, Arg280His, Arg399Gln) and the incidence risk of gliomas. Firstly, studies which related to the genetic polymorphisms of XRCC1 and glioma susceptibility were searched for in PubMed, Cochrane, CBM, Wanfang, and CNKI databases. Then the related data was extracted and analyzed by Revman 5.3 software. Finally, 19 case-control studies involving 7,024 glioma patients and 8,425 control subjects were included. The cumulative meta-analysis showed that there is no obvious association between XRCC1 Arg194Trp or Arg280His polymorphisms and a high risk of gliomas, but the Arg399Gln polymorphism of XRCC1 may be an important factor in the development of gliomas, especially in an Asian population.